biotech · Fabry Disease · Bioequivalence · PLX
Protalix Biotherapeutics
Protalix BioTherapeutics
Protalix Biotherapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
- Founded
- 1994
- Employees
- 197
- Programs
- 21
- Drugs
- 14
- Patents
- 22
Protalix Biotherapeutics projects
7 ClinicalTrials.gov programs sponsored by Protalix Biotherapeutics.
Protalix Biotherapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AIR DNase
Protalix BioTherapeutics
Cystic Fibrosis (CF)
1 trial -
Aspirin
Protalix BioTherapeutics
Bioequivalence
1 trial -
Human Glucocerebrosidase (prGCD)
Protalix BioTherapeutics
Gaucher Disease
1 trial -
OPRX-106
Protalix BioTherapeutics
Human Volunteer
1 trial -
PL2200 fasted
Protalix BioTherapeutics
Healthy
1 trial -
PRX-105
Protalix BioTherapeutics
Organophosphate Exposure
1 trial -
Pharmaceutical-lipid aspirin (PL-ASA)
Protalix BioTherapeutics
Bioequivalence
1 trial
Frequently asked questions
How many clinical projects does Protalix Biotherapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.